BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32661830)

  • 1. Evaluation of [
    Tsai WK; Zettlitz KA; Dahlbom M; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Oct; 22(5):1380-1391. PubMed ID: 32661830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Zettlitz KA; Tsai WK; Knowles SM; Salazar FB; Kobayashi N; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Apr; 22(2):367-376. PubMed ID: 31209779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.
    Knowles SM; Zettlitz KA; Tavaré R; Rochefort MM; Salazar FB; Stout DB; Yazaki PJ; Reiter RE; Wu AM
    J Nucl Med; 2014 Mar; 55(3):452-9. PubMed ID: 24504052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody.
    Tsai WK; Zettlitz KA; Tavaré R; Kobayashi N; Reiter RE; Wu AM
    Theranostics; 2018; 8(21):5903-5914. PubMed ID: 30613270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer.
    Knowles SM; Tavaré R; Zettlitz KA; Rochefort MM; Salazar FB; Jiang ZK; Reiter RE; Wu AM
    Clin Cancer Res; 2014 Dec; 20(24):6367-78. PubMed ID: 25326233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.
    Lepin EJ; Leyton JV; Zhou Y; Olafsen T; Salazar FB; McCabe KE; Hahm S; Marks JD; Reiter RE; Wu AM
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1529-38. PubMed ID: 20354850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Characterization of the
    Striese F; Neuber C; Gräßel S; Arndt C; Ullrich M; Steinbach J; Pietzsch J; Bergmann R; Pietzsch HJ; Sihver W; Frenz M; Feldmann A; Bachmann MP
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting angiogenesis for radioimmunotherapy with a
    Ehlerding EB; Lacognata S; Jiang D; Ferreira CA; Goel S; Hernandez R; Jeffery JJ; Theuer CP; Cai W
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):123-131. PubMed ID: 28821931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
    Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
    Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
    Korsen JA; Gutierrez JA; Tully KM; Carter LM; Samuels ZV; Khitrov S; Poirier JT; Rudin CM; Chen Y; Morris MJ; Bodei L; Pillarsetty N; Lewis JS
    Proc Natl Acad Sci U S A; 2022 Jul; 119(27):e2203820119. PubMed ID: 35759660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of the theranostic potential of
    Wu Y; Li T; Zhang X; Jing H; Li F; Huo L
    EJNMMI Radiopharm Chem; 2024 Jan; 9(1):5. PubMed ID: 38194043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors.
    Leyton JV; Olafsen T; Lepin EJ; Hahm S; Bauer KB; Reiter RE; Wu AM
    Clin Cancer Res; 2008 Nov; 14(22):7488-96. PubMed ID: 19010866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors.
    Bäck TA; Jennbacken K; Hagberg Thulin M; Lindegren S; Jensen H; Olafsen T; Yazaki PJ; Palm S; Albertsson P; Damber JE; Wu AM; Welén K
    EJNMMI Res; 2020 Feb; 10(1):10. PubMed ID: 32048062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate
    Maaland AF; Heyerdahl H; O'Shea A; Eiriksdottir B; Pascal V; Andersen JT; Kolstad A; Dahle J
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2311-2321. PubMed ID: 31309259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
    Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
    J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models.
    Zhang M; Kobayashi N; Zettlitz KA; Kono EA; Yamashiro JM; Tsai WK; Jiang ZK; Tran CP; Wang C; Guan J; Wu AM; Reiter RE
    Clin Cancer Res; 2019 Jan; 25(1):188-200. PubMed ID: 30301826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.